Skip to main content
SCHIZOPHRENIA 1 (Disorder)Cognitive functionMental healthDrugPhase 2

What this study is

The investigators aim to determine the effects of a novel drug on brain function and brain chemistry in patients with schizophrenia.

What's being tested

  • DSP-2342

    Intervention · DRUG

    a single oral dose of DSP-2342 on brain chemistry and brain activity in adults with schizophrenia.

Study details

Sponsor
Johns Hopkins University
Conditions
SCHIZOPHRENIA 1 (Disorder)
Enrolling
20 people
Starts
2027-01-01
Est. completion
2028-06-30
Design
Open-label, single group, Phase 2
Record
View on ClinicalTrials.gov ↗